HN2011001247A - Inhibidores de cinana akt y p70 s6 - Google Patents

Inhibidores de cinana akt y p70 s6

Info

Publication number
HN2011001247A
HN2011001247A HN2011001247A HN2011001247A HN2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A
Authority
HN
Honduras
Prior art keywords
inhibitors
cinana
akt
formula
compounds
Prior art date
Application number
HN2011001247A
Other languages
English (en)
Spanish (es)
Inventor
Dean Dally Robert
Joseph Sajan
Alan Shepherd Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001247A publication Critical patent/HN2011001247A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HN2011001247A 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6 HN2011001247A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
HN2011001247A true HN2011001247A (es) 2013-05-20

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001247A HN2011001247A (es) 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (cg-RX-API-DMAC7.html)
EP (1) EP2358710B1 (cg-RX-API-DMAC7.html)
JP (1) JP5432275B2 (cg-RX-API-DMAC7.html)
KR (1) KR101334460B1 (cg-RX-API-DMAC7.html)
CN (1) CN102216302B (cg-RX-API-DMAC7.html)
AR (1) AR074072A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314324B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921916A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743019C (cg-RX-API-DMAC7.html)
CO (1) CO6382114A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110240A (cg-RX-API-DMAC7.html)
CY (1) CY1113409T1 (cg-RX-API-DMAC7.html)
DK (1) DK2358710T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000129A (cg-RX-API-DMAC7.html)
EA (1) EA018947B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011048A (cg-RX-API-DMAC7.html)
ES (1) ES2391704T3 (cg-RX-API-DMAC7.html)
HN (1) HN2011001247A (cg-RX-API-DMAC7.html)
HR (1) HRP20120738T1 (cg-RX-API-DMAC7.html)
IL (1) IL211940A (cg-RX-API-DMAC7.html)
JO (1) JO2822B1 (cg-RX-API-DMAC7.html)
MA (1) MA32776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005000A (cg-RX-API-DMAC7.html)
MY (1) MY161461A (cg-RX-API-DMAC7.html)
NZ (1) NZ592062A (cg-RX-API-DMAC7.html)
PA (1) PA8846901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20110807A1 (cg-RX-API-DMAC7.html)
PL (1) PL2358710T3 (cg-RX-API-DMAC7.html)
PT (1) PT2358710E (cg-RX-API-DMAC7.html)
RS (1) RS52520B (cg-RX-API-DMAC7.html)
SI (1) SI2358710T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000207A1 (cg-RX-API-DMAC7.html)
TW (1) TWI422587B (cg-RX-API-DMAC7.html)
UA (1) UA100190C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102549B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
EP3299362B1 (en) * 2012-11-16 2020-04-22 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2746756T3 (es) * 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
MX374576B (es) * 2016-05-20 2025-03-06 Taiho Pharmaceutical Co Ltd Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso.
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
JPWO2024009977A1 (cg-RX-API-DMAC7.html) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
PL2358710T3 (pl) 2012-12-31
AU2009314324A1 (en) 2010-05-20
WO2010056563A1 (en) 2010-05-20
MY161461A (en) 2017-04-14
US8148387B2 (en) 2012-04-03
TN2011000207A1 (en) 2012-12-17
EA018947B1 (ru) 2013-11-29
ZA201102549B (en) 2012-09-26
AU2009314324B2 (en) 2013-06-20
TW201022268A (en) 2010-06-16
PT2358710E (pt) 2012-10-01
ES2391704T3 (es) 2012-11-29
HRP20120738T1 (hr) 2012-10-31
EP2358710A1 (en) 2011-08-24
KR101334460B1 (ko) 2013-12-02
BRPI0921916A2 (pt) 2015-12-29
RS52520B (sr) 2013-04-30
CY1113409T1 (el) 2016-06-22
HK1158203A1 (en) 2012-07-13
DOP2011000129A (es) 2016-02-29
CN102216302B (zh) 2013-08-21
IL211940A (en) 2014-01-30
AR074072A1 (es) 2010-12-22
CN102216302A (zh) 2011-10-12
CA2743019A1 (en) 2010-05-20
ECSP11011048A (es) 2011-06-30
MA32776B1 (fr) 2011-11-01
IL211940A0 (en) 2011-06-30
CA2743019C (en) 2013-08-13
JO2822B1 (en) 2014-09-15
CO6382114A2 (es) 2012-02-15
CR20110240A (es) 2011-06-09
UA100190C2 (en) 2012-11-26
JP5432275B2 (ja) 2014-03-05
EP2358710B1 (en) 2012-08-15
SI2358710T1 (sl) 2012-11-30
DK2358710T3 (da) 2012-09-03
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13
TWI422587B (zh) 2014-01-11
NZ592062A (en) 2013-03-28
EA201170680A1 (ru) 2011-12-30
PE20110807A1 (es) 2011-10-31
MX2011005000A (es) 2011-05-25
KR20110074578A (ko) 2011-06-30
JP2012508274A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
ECSP099721A (es) Inhibidores de cinasa p70 s6
CR10782A (es) Compuestos para inhibir la progresion mitotica
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BR112012011328A2 (pt) inibidores de akt
UY33735A (es) Compuestos antivirales
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
GT200900027A (es) Compuestos organicos
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
GT200600117A (es) Nuevos compuestos farmaceuticos
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
PA8846401A1 (es) Sinergismo antibiótico
UY31487A1 (es) Derivados de pirazol como inhibidores de 5-lo
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.